LOVASTATIN tablet

Pajjiż: Stati Uniti

Lingwa: Ingliż

Sors: NLM (National Library of Medicine)

Ingredjent attiv:

LOVASTATIN (UNII: 9LHU78OQFD) (LOVASTATIN - UNII:9LHU78OQFD)

Disponibbli minn:

Proficient Rx LP

INN (Isem Internazzjonali):

LOVASTATIN

Kompożizzjoni:

LOVASTATIN 20 mg

Rotta amministrattiva:

ORAL

Tip ta 'preskrizzjoni:

PRESCRIPTION DRUG

Indikazzjonijiet terapewtiċi:

Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See Error! Hyperlink reference not valid. ). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower

Sommarju tal-prodott:

Lovastatin Tablets USP, 20 mg are light green colored, circular, beveled edged, uncoated tablets, debossed with 'LU' on one side and 'G02' on the other side. They are supplied as follows: Storage Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Lovastatin tablets must be protected from light and stored in a well-closed, light-resistant container. 1     Kantola, T, et al., Clin Pharmacol Ther 1998; 63(4): 397-402 3    Manson, J.M., Freyssinges,C.Ducrocq, M.B., Stephenson, W.P., Postmarketing Surveillance of Lovastatin and Simvastatin Exposure During Pregnancy. Reproductive Toxicology. 10(6):439-446, 1996. 4    National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics . 89(3):495-501. 1992. Manufactured for Lupin Pharmaceuticals, Inc.  Baltimore, Maryland 21202 United States Manufactured by Lupin Limited  Goa 403 722 INDIA Repackaged by: Proficient Rx LP Thousand Oaks, CA 91320 Revised: June 2014                                                                                         ID#: 237790

L-istatus ta 'awtorizzazzjoni:

Abbreviated New Drug Application

Karatteristiċi tal-prodott

LOVASTATIN- LOVASTATIN TABLET
PROFICIENT RX LP
----------
LOVASTATIN TABLETS USP
20 MG
RX ONLY
DESCRIPTION
Lovastatin is a cholesterol lowering agent isolated from a strain of
_Aspergillus terreus._
After oral ingestion, lovastatin, which is an inactive lactone, is
hydrolyzed to the
corresponding β-hydroxyacid form. This is a principal metabolite and
an inhibitor of 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme
catalyzes the
conversion of HMG-CoA to mevalonate, which is an early and rate
limiting step in the
biosynthesis of cholesterol.
Lovastatin is [1_S_-[1α(_R_ ),3α,7β,8β(2_S_ ,4_S_
),8aβ]]-1,2,3,7, 8,8a-hexahydro-3,7-dimethyl-
8-[2-(tetrahydro-4-hydroxy-6-oxo-2_H_-pyran-2-yl)ethyl]-1-naphthalenyl
2-
methylbutanoate. The empirical formula of lovastatin is C
H
O and its molecular
weight is 404.55. Its structural formula is:
Lovastatin is a white, nonhygroscopic crystalline powder that is
insoluble in water and
sparingly soluble in ethanol, methanol, and acetonitrile.
Lovastatin tablets USP are supplied as 20 mg tablets for oral
administration. In addition
to the active ingredient lovastatin, each tablet contains the
following inactive ingredients:
D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake,
lactose anhydrous,
lactose monohydrate, magnesium stearate, microcrystalline cellulose
and pregelatinized
corn starch. Butylated hydroxyanisole (BHA) is added as a
preservative.
CLINICAL PHARMACOLOGY
The involvement of low-density lipoprotein cholesterol (LDL-C) in
atherogenesis has been
well-documented in clinical and pathological studies, as well as in
many animal
experiments. Epidemiological and clinical studies have established
that high LDL-C and
low high-density lipoprotein cholesterol (HDL-C) are both associated
with coronary heart
disease. However, the risk of developing coronary heart disease is
continuous and
graded over the range of cholesterol levels and many coronary events
do occur in
patients with total cholesterol (total-C) and LDL-C in the lower end
of this